Advertisement

FMS

Fresenius Medical Care AG

Healthcare · USD

Set alert

Price alert · FMS

All alert types
22.47 USD -0.66 -2.85%
As of Oct 30, 2026 Extended hours 22.47 0.00%
Bid
22.46 × 600
Ask
22.47 × 500
22.45 Day range 22.89
20.19 52-week range 26.84
YTD
-5.67%
1 year
-15.78%
Open
22.82
Prev close
23.13
Mkt cap
11.96B
Vol
967.97K
Avg vol
923.86K
EPS
1.94
P/E
11.58
Div yield
3.77%
More statistics
Low
22.45
High
22.89
Forward P/E
7.55
Beta
0.81
Short ratio
4.08
Inst. own
9.96%
Dividend
0.87
Ex-div date
May 21, 2026
Earnings
Nov 3, 2026
50-d avg
22.41
200-d avg
22.87
1y target
23.77

2Y chart

Chart tools
Interval
FMS two-year price chart19.322.124.927.730.5Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
11.96B
Enterprise value
23.20B
Trailing P/E
11.58
Forward P/E
7.55
PEG ratio
0.77
Price / sales
0.62
Price / book
0.85
EPS (TTM)
1.94
Beta
0.81
Dividend yield
3.77%
Payout ratio
45.01%
Profit margin
4.83%
Revenue (TTM)
19.43B
Revenue growth
1.40%
Free cash flow
2.02B
Total cash
1.06B
Total debt
10.98B
Return on equity
8.52%
Shares outstanding
532.22M
Short % of float
0.00%
50-day average
22.41
200-day average
22.87

Analyst view

Consensus: hold

Hold
Price target (mean) 23.77 +5.8% upside
Target (low)
17.27
Target (mean)
23.77
Target (high)
37.78
Ratings (0m) 7 1 buy · 3 hold · 3 sell
  • Strong buy0
  • Buy1
  • Hold3
  • Sell1
  • Strong sell2

Next earnings

Nov 3, 2026

Expected Nov 3, 2026. Consensus EPS estimate 0.529.

Earnings history

Financials — quick view

All financials
FMS Revenue — quarterly 4.86B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
FMS Net income — quarterly 218.38M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
FMS EPS — quarterly 0.405
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

FMS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 3, 2026Sep 30, 20260.651———
Aug 3, 2026Jun 30, 20260.6160.66+0.04+7.14%
May 5, 2026Mar 31, 20260.590.53-0.06-10.17%
Feb 24, 2026Dec 31, 20250.6470.83+0.18+28.28%
Nov 4, 2025Sep 30, 20250.590.64+0.05+8.47%
Aug 5, 2025Jun 30, 20250.500.52+0.02+4.00%

Upgrades / downgrades

FMS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026Truist SecuritiesmainHoldHold
Aug 6, 2026BernsteinmainMarket PerformMarket Perform
Sep 2, 2025UBSdownNeutralSell
May 12, 2025Truist SecuritiesmainHoldHold
Jan 6, 2025Truist SecuritiesmainHoldHold
Oct 7, 2024Truist SecuritiesmainHoldHold

About Fresenius Medical Care AG

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Sector
Healthcare
Industry
Medical Care Facilities
Country
Germany

News

Your note

Sign in to keep a note on FMS — it syncs with the Stock Master app.

Institution ownership

FMS institution ownership
Holder% heldSharesValueReported
Pzena Investment Management LLC2.82%14,992,081336.87MJun 29, 2026
Morgan Stanley0.82%4,347,74897.69MJun 29, 2026
Dodge & Cox Inc.0.72%3,826,91085.99MJun 29, 2026
Fiduciary Management, Inc.0.55%2,937,82966.01MJun 29, 2026
Brandes Investment Partners L.P.0.36%1,916,09043.05MJun 29, 2026
Todd Asset Management LLC0.33%1,761,48339.58MSep 29, 2026

Fund ownership

FMS fund ownership
Holder% heldSharesValueReported
VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund1.54%8,204,589184.36MJul 30, 2026
Dodge & Cox Funds-Dodge & Cox Balanced Fund0.72%3,826,91085.99MJun 29, 2026
VANGUARD WHITEHALL FUNDS-Vanguard Selected Value Fund0.48%2,539,43157.06MJul 30, 2026
Liberty All Star Equity Fund0.21%1,125,29225.29MJun 29, 2026
FMI Funds Inc-Large Cap Fund0.19%1,030,00023.14MJun 29, 2026
John Hancock Capital Series-Classic Value Fund0.16%874,36219.65MAug 30, 2026
Advertisement